Matrivax Initiates Phase 1 Clinical Development of MVX01, a Novel Pneumococcal Vaccine Candidate
First participant dosed in a Phase 1 clinical evaluation of a fusion protein vaccine designed to provide ‘serotype-independent' protection against disease caused by multiple Streptococcus pneumoniae serotypes Vaccine development company Matrivax …